Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS

A Randomized, Multi-center, Double-blind, Placebo Controlled, Dose Ranging Study With VSL#3 in Diarrhea Predominant IBS Patients

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00179582

Enrollment

180

Registered

2005-09-16

Start date

2005-01-31

Completion date

2006-01-31

Last updated

2019-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IBS

Keywords

IBS, Functional bowel disorder, Diarrhea, probiotic

Brief summary

To evaluate the effects of VSL#3 on symptoms associated with diarrhea predominant IBS

Detailed description

The study will evaluate 2 doses of VSL#3 and placebo over a 4 week period in patients presenting with diarrhea predominant IBS symptoms.

Interventions

DRUGVSL#3

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* IBS diarrhea

Exclusion criteria

* \< 18 years of age * Pregnancy/breast feeding * concomitant medications to reduce bowel function

Design outcomes

Primary

Measure	Time frame
Global improvement in IBS symptoms	—

Secondary

Measure	Time frame
Frequency of bowel movements	—
Changes in abdominal pain	—
Changes in bloating	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026